* Q2 adjusted EPS $1.38 vs Street view $1.30

* 2010 revenue view lowered slightly due to weaker euro

* Says Prolia Europe, U.S. launches progressing

* Shares unchanged

(Adds company comment, updates share price)

By Bill Berkrot

NEW YORK (Reuters) - Amgen Inc reported
better-than-expected second-quarter profit on Thursday and the
world's largest biotechnology company said the launch of its
new osteoporosis drug Prolia was progressing as planned.

Sales of some of its most important products fell short of
Wall Street estimates, with the anemia drug Aranesp declining
more than anticipated, and the company slightly lowered its
full-year revenue forecast.

But shares barely moved as investors were already looking
ahead to focus on Prolia, which was approved on June 1 in the
United States days after European approval. It is widely
expected to be Amgen's most important future growth driver.

"The launches are progressing both in Europe and the United
States as we had planned. The initial feedback from physicians
has been positive," Chief Executive Kevin Sharer told analysts
and investors on a conference call.

The company is hoping for an additional U.S. approval for
the drug, also known as denosumab, as soon as November for
reducing fractures and other skeletal problems in patients
whose cancer has spread to the bone.

Amgen expects Prolia approvals in Canada and Switzerland in
the current quarter, and said the drug was "off to a strong
start in Germany," where it has received government
reimbursement.

"In short order we will be pursuing Prolia launches around
the globe," said research chief Roger Perlmutter.

Excluding items, the company had second-quarter adjusted
earnings of $1.38 per share, topping analysts' average
expectations by 8 cents per share, according to Thomson Reuters
I/B/E/S.

Amgen posted a net profit of $1.20 billion, or $1.25 per
share, compared with a profit of $1.27 billion, or $1.25 per
share, a year earlier.

"This was every bit the mixed quarter that people expected
it to be, and with the quarter behind us people will look
forward to better times at Amgen, specifically the data on
denosumab expected later this year," said Cowen and Co analyst
Eric Schmidt.

Revenue for the quarter was $3.8 billion, just ahead of
Wall Street estimates of $3.74 billion.

But the company said due to the impact of a weaker euro it
now expects full-year revenue to come in slightly below $15.1
billion, which had been the bottom of its prior forecast
range.

Amgen continues to expect 2010 adjusted earnings at the low
end of its forecast range of $5.05 to $5.25 per share.

Sales of Aranesp, which have been under assault due to
safety concerns and reimbursement restrictions, fell 13 percent
to $603 million, well short of analysts' expectations of $640.9
million. But sales of the older red blood cell booster Epogen
rose 3 percent to $657 million, exceeding Wall Street estimates
of $653.4 million.

The company said most safety and use restriction issues for
its anemia franchise "have been addressed or resolved," adding
that it has a lot more clarity for the business going forward.

Sales of the rheumatoid arthritis drug Enbrel also were a
bit disappointing, falling 2 percent to $877 million, just shy
of estimates for $879.5 million. Enbrel is a medicine that has
often exceeded expectations in past quarters.

Combined worldwide sales of the white blood cell boosters
Neupogen and Neulasta rose 1 percent to $1.17 billion, while
Wall Street was looking for $1.19 billion.

"Most of the products fell a little short of expectations,"
said Schmidt, noting "pressures out of Europe both on foreign
exchange and on pricing."

"But they protected you on the bottom line with some nice
cost savings and they will continue to do so for the remainder
of the year," he said.

After fluctuating slightly in extended trading, Amgen
settled at $53.37, matching their Nasdaq close.
(Reporting by Bill Berkrot; Editing by Gary Hill)